Abstract To establish for the first time how mice might differ from rats and humans in
Introduction
Copper is an obligatory trace element in all living organisms and has been identified as important for the functions of a discrete number of redox enzymes involved in varied aspects of mammalian metabolism. These include mitochondrial cytochrome c oxidasethe terminal step of respiration; dopamine-beta-monooxygenase and alpha-amidating enzyme-required for the formation of specific neurotransmitters; lysyl oxidase-needed for the cross-linking maturation of collagen and elastin in connective tissue; tyrosinasewhich helps to form the pigment, melanin; and Cu/Zn superoxide dismutase and ceruloplasmin-which protect against reactive oxygen species (Harris 2000; Linder 1991 Linder , 2002 . More recently, many copper binding proteins necessary for its uptake and transport have been identified, including the membrane transporters, CTR1 (Kuo et al. 2001; Lee et al. 2001 ) and DMT1 (Fleming et al. 1998; Gunshin et al. 1997) ; the copper ''chaperones'' HAH1, CCS and COX17 that shuttle Cu through the cytoplasm to specific sites (Amaravadi et al. 1997; Culotta et al. 1997; Huffman and O'Halloran 2001; Klomp et al. 1997; Linder 2002) ; and the copper ''pumps'' ATP7A and B that are defective in Menkes and Wilson diseases, respectively (Camakaris et al. 1999; Mercer 2001; Puig and Thiele 2002) . Liver ATP7B is particularly important in helping mammals such as rats and humans efficiently eliminate excess copper (Linder and Roboz 1986; Turnlund et al. 1989 Turnlund et al. , 1998 in the bile (Roelofsen et al. 2000; Schaefer et al. 1999 ) in a relatively nonre-absorbable form (Linder 1991) . In the absence of effective ATP7B, Cu accumulates, particularly in the liver, causing cirrhosis and reduced organ function, leading to an early death in those with this genetic trait (Wilson disease). The identity and role of all the participants needed to transport excess copper to the bile are not yet understood; and other gene products must also be involved, including MURR1/COMMD1 (Burstein et al. 2005; Klomp et al. 2003) , a multifunctional protein defective in the Bedlington terrier, a lack of which also results in liver copper accumulation and toxicity. In rats and humans, however, the ability to excrete excess copper via the bile is well developed and largely responsible for maintenance of whole body copper homeostasis (Linder 2001) . Thus, there is only short-term storage of excess copper (in metallothionein), and excesses are readily excreted, as shown in rats with whole body counting after administration of radioactive 67 Cu (Linder and Roboz 1986) and in humans with the stable isotopic 65 Cu (Turnlund et al. 1989 (Turnlund et al. , 1998 . It has long been known that ceruloplasmin is the main copper-binding component in the blood plasma and most other body fluids of the mammal. This blue, multi-copper oxidase appears to have pleotropic functions and has been referred to as a prototypic ''moonlighting'' protein (Bielli and Calabrese 2002) , capable of oxidizing a variety of substrates-from amines to Fe(II) (Harris 2000; Linder 1991 Linder , 2002 ; scavenging radicals (Linder 2001 (Linder , 2002 ; and delivering copper to tissues (Campbell et al. 1981; Lee et al. 1993) , probably via specific receptors (Kataoka and Tavassoli 1985; Linder 2002; Stevens et al. 1984) . Its apparent role in Fe transport (attributed to its ferroxidase activity) has been of particular recent interest. Thus, in humans (Harris et al. 1995 (Harris et al. , 1998 Yoshida et al. 1995) or mice (Harris et al. 1999) lacking ceruloplasmin genetically or through severe Cu deficiency (Linder 1991 (Linder , 2002 Osaki and Johnson 1969; Ragan et al. 1969) there is a gradual accumulation of excess iron in certain tissues, including the liver and retina, resulting in tissue damage. This has been explained on the basis that ceruloplasmin oxidizes Fe(II) as it leaves cellular storage sites, promoting the binding of the resulting Fe(III) to its blood plasma transporter, transferrin (Frieden 1970; Linder 1991) . This concept is supported by experimental evidence that intravenous infusion of ferroxidase-active ceruloplasmin into organs of ceruloplasmin-deficient dogs (Osaki and Johnson 1969) or pigs (Ragan et al. 1969 ) results in the immediate release of iron into the blood, although it appears that only extremely low levels of active ceruloplasmin (\1% of normal) reduce iron transport and accumulation (Roeser et al. 1980) .
In human and rat blood, ceruloplasmin accounts for approximately 70% of the total copper in the plasma (Barrow and Tanner 1988; Weiss and Linder 1985; Wirth and Linder 1985) rather than the 95% usually quoted. The remainder of the Cu is thought to be associated mainly with two other proteins that may make up most of the exchangeable copper pool in blood fluids. These are albumin, which in most mammals has a single, high affinity copper-binding site at its N-terminus involving a crucial histidine (Linder 1991 (Linder , 2002 ; and a macroglobulin, designated alpha-1-inhibitor-3 in rodents and alpha-2-macroglobulin in humans (Liu et al. 2007 ). The macroglobulins have an even higher affinity for copper than albumin, and rapidly exchange copper with the latter, in vitro (Linder 1991 (Linder , 2002 Trang Nguyen, Mizue Moriya, Ann Grana, Mimi Mak and Maria Linder unpublished results) . Traces of other copper containing proteins are also present in human plasma/serum (Linder 1991) , although their contributions to total plasma/serum copper is unclear. These include metallothionein, ferroxidase II, blood clotting factors V and VIII, extracellular SOD and amine oxidase, as well as possibly histidine-rich glycoprotein and unknown small peptides (Linder 1991 (Linder , 2002 .
In the cell cytoplasm, several prominent copper binding proteins have also been separated by size exclusion chromatography (Freedman et al. 1989; Harris 2000; Norton and Heaton 1980; Sharma and McQueen 1981; Terao and Owen 1973) . The two most commonly identified are Cu/Zn SOD (about 35,000 Da) and metallothionein (Mr about 15,000), although the previously mentioned (similar-sized) ''chaperones'' (HAH1, CCS, COX17) for shuttling copper to specific intracellular sites (Amaravadi et al. 1997; Culotta et al. 1997; Huffman and O'Halloran 2001; Klomp et al. 1997) , and some other already mentioned soluble copper proteins/enzymes, are also present. A large ([100 kDa) unknown component has also commonly been observed.
Most of the information about copper in the various proteins described and the kinetics of its transport and excretion has been obtained from trace analysis of the copper in tissues and by following the distribution of radioactive copper in rats (Linder 1991 (Linder , 2002 Terao and Owen 1973) . In humans, there have also been some studies using the stable isotope, 65 Cu (Turnlund et al. 1989 (Turnlund et al. , 1998 . Today, because of its size and ease of genetic manipulation, the mouse is the most widely used organism to model the transport and metabolism of specific nutrients or metabolites in humans; yet the Cu metabolism of mice is not well studied, particularly with regard to copper transport and blood plasma binding components. Indeed, earlier experimental work from our laboratory (Montaser et al. 1992 ) and that of Prohaska (1983) indicated that copper metabolism in the mouse might differ from that in humans and rats. Thus, the first objective of the studies reported here was to examine this issue. To accomplish this, size exclusion high performance liquid chromatography directly coupled to ICP-MS (inductively coupled plasma mass spectrometry) was used to compare the copper binding components in blood plasma from mice, humans and rats, as well as in cytosols of a variety of organs. This technique was also used to monitor the biochemical responses and long-term fluxes of copper, into and out of organs of the mice, after a large i.p. injection of 65 Cu. This stable isotope has been used in low doses in mice to study hepatic Cu turnover (Ting et al. 1990 ) but has not been used for temporal analyses to study Cu turnover in the blood or other organs (or their individual components). The results reported here are the first showing that the mouse differs considerably from the rat and human with regard to the proportions of copper associated with various plasma proteins; that the major mouse cytoplasmic binding proteins responsible for coping with larger doses of extraneous copper are similar to those previously reported in the rat; and that with high doses of Cu, it is possible to obtain significant, but not substantial, enrichments of copper proteins in organs peripheral to the liver.
Materials and methods

Materials
The stable isotope, 65 Cu, was obtained as CuO from Oak Ridge National Laboratory (Oak Ridge, TN). 64 (Lee et al. 1993; Weiss and Linder 1985) , and comparing its tissue and protein distribution after i.v. administration to rats (Vargas et al. 1994; Weiss and Linder 1985) . Euthanization was by bleeding from the vena cava under pentobarbital anesthesia after treatment with heparin, as previously described (Linder and Roboz 1986; Weiss and Linder 1985) . Plasma was prepared and stored as described above. Liver, kidney, heart, lungs, spleen and brain were collected and homogenized with trace metal grade 0.15M NH 4 Cl. Tissue cytoplasm was obtained after centrifugation for 1 h at 105,000g in a Beckman L8-70M ultracentrifuge, at 4°C. Portions of homogenate and cytoplasm were stored at -80°C until analyzed. Plasma was also obtained from normal adult, female Fisher and male Sprague Dawley rats, euthanized and bled as described for the mice.
Tissue, cytoplasm and plasma copper analysis For total Cu isotope quantitation, either 100 or 250 ll portions of homogenate or cytoplasm, respectively, were dried to a constant weight at 60°C in acidwashed disposable tubes (Cat. No. 14-958-C; Fisher Scientific), then wet ashed on a hot plate with 250 ll of ultrapure concentrated HNO 3 until almost dry. Residues were dissolved in 4.5 ml of 2% ultrapure HNO 3 containing 10 ppb of internal standards (Ga, In, Tl and Y) . Serum was diluted 100-fold with the same acid-internal standard solution. Individual Cu isotopes were quantified using a Perkin Elmer 6100 DRC ICP-MS from standard curves of Cu generated from dilutions of a multi-element standard with known isotopic ratios of 63 63 Cu content of the sample using the 63 Cu: 65 Cu isotope ratio in equivalent control samples. The extrinsic 65 Cu was determined by difference (total 65 Cu minus the calculated intrinsic 65 Cu content).
Electrophoresis and Western blotting SDS-PAGE was carried out in 7% acrylamide resolving gels by standard procedures and transferred to PVDF membranes (BioRad) by semi-dry transfer (BioRad), in Tris Triton buffered saline, as previously described (Donley et al. 2002) . Blocking was with 5% dry milk protein. Primary antibodies were raised in rabbits against human ceruloplasmin and albumin were from Dako (Carpinteria, CA). Secondary antibody was AP-conjugated goat-anti-rabbit IgG, from BioRad. Densitometry of immunoblots was performed with the BioRad Gel Doc XR System with Quantity One software.
Protein analysis
Protein content was determined using a Bradford dye binding assay (BioRad, Richmond, CA) and bovine serum albumin as a standard.
Directly coupled size exclusion HPLC-ICP-MS
Chromatographic separations and isotopic determination of samples were performed using a ''biocompatible'' Beckman 126 programmable solvent delivery module equipped with a Beckman 168 diode array UV/Vis detector that was directly coupled to ICP-MS (Mason and Borja 2002) . PEEK @ tubing was used to connect the components in the system. Aspiration was through a quartz Meinhard concentric nebulizer and a cyclonic spray chamber. Standard curves for apparent molecular weight (Mr) were obtained using gel filtration standards that included thyroglobulin (670 kDa), ferritin (480 kDa), bovine gamma-globulin (158 kDa), human ceruloplasmin (132 kDa), chicken ovalbumin (44 kDa), equine myoglobin (16.7 kDa), and vitamin B12 (1.34 kDa). Samples (100 ll) of 5-fold diluted plasma or tissue cytosol were filtered (0.45 lm) and fractionated isocratically (20 mM Tris Á HCl, pH 7.4) by size exclusion chromatography, using either a Biosep 2000 or 4000 SEC column (Phenomenex, Torrance, CA), or in some cases on 1 9 25 or 30 cm columns of Sephacryl S300 or Sephadex G150. The isotopic ratio of 63 Cu: 65 Cu of the various peaks was determined at the centroid value of each peak. Analyses of samples from control animals showed protein peaks with 63 Cu:
65 Cu ratios that were attenuated relative to the measured natural abundance of the Cu standards, indicating some inerference and augmentation of the signal at M/Z 65 from polyatomic adducts, possibly 48 Ca 16 O 1 H generated from the buffer.
Statistics
Statistical analysis of the data was by one way ANOVA. Probability (P) values of \0.05 were considered significant.
Results
Comparisons of the copper binding components of mouse plasma in comparison with those of humans and rats
The distribution of copper among binding proteins of the blood plasma of the mouse has not been previously examined. To do this and compare the mouse with the more comprehensively studied rat and human systems, fresh and previously frozen samples from adult, female C57BL6 mice and from normal adult humans and rats were separated by HPLC size exclusion chromatography and analyzed by UV/Vis spectroscopy prior to coupled ICP-MS elemental analysis. This approach was taken as well to obtain more refined data for copper binding components in all three species than previously available in the literature. Initial fractionation of rat and human plasma using a Biosep 2000 column showed one major copper-containing peak, eluting at 11.3 min, having a narrow shoulder coinciding with the void volume (10.6 min) (Fig. 1a) . Another (smaller) component eluted at about 14 min. The Mr of the major (11.3 min) and minor (14 min) components were 124 k and 72 k, respectively, which approximate to the molecular weights for ceruloplasmin (132 k) and albumin (69 kDa), respectively. Fractionation of mouse plasma (Fig. 1b) showed more copper associated with the presumed albumin peak (around 14 min) and proportionately less with ceruloplasmin, although the latter still predominated. In addition to this difference in Cu distribution, the overall copper content of mouse plasma was considerably lower than that of the human and rat. Concentrations of total copper (ng/ml) in the mouse samples were 400 ± 160 (Mean ± SD; N = 4), whereas those of humans and rats were in the range of 1000-1200 ng/ml (Lee et al. 1993) .
To facilitate further separation of the larger proteins (including the macroglobulins) from ceruloplasmin, the plasma samples were fractionated on a Biosep 4000 column (Fig. 2) . Typically, five copper peaks could be observed in chromatograms from fresh or frozen (not shown) samples of mouse plasma using this column (Fig. 2a) . Beginning soon after the void volume, there was a small shoulder of copper Cu (solid line) with transcuprein (peak 1) and albumin (peak 2) from a 1 9 30 cm column of Sephadex G150, following addition of 64 Cu(II)-NTA (1:3 molar ratio) to 0.5 ml mouse plasma. A 280 is also indicated (dashed line) (peak 1) followed by a significant minor peak (peak 2) eluting at 15.5 min. The latter accounted for about 8% of the total copper and had an Mr of about 300 k (Fig. 2b) . This is consistent with the macroglobulin, alpha-1-inhibitor-3 (Liu et al. 2007 ) which we have previously identified as the important copper transport protein in rat plasma, transcuprein, of Mr 270 k (Vargas et al. 1994; Weiss and Linder 1985) . Peak 3 (Fig. 2a) eluted at 16.8 min with a Mr of approximately 190 k, contained about 55% of the plasma copper, and was tentatively identified as ceruloplasmin on the basis that it was markedly diminished in the plasma of knockout mice (data not shown). Peak 4 contained approximately 25% of the total plasma copper, and eluted at 18.8 min (Mr 78 k) just ahead of pure hemoglobin standard (64 kDa) (Fig. 2c) , consistent with it being albumin. The final copper peak eluted as a broad shoulder centered around 22.5 min (approximately 15 kDa). The significance of mouse albumin for copper binding was further established by comparing the copper elution profile before and after treatment of mouse plasma with Cibacron Blue affinity gel (known to remove albumin specifically; Ma et al. 2005) . A sizeable proportion of the total copper (about 20%) was removed in the region where albumin elutes (Fig. 2d) . Copper was removed not only from the albumin ''shoulder'' but also from the region where ceruloplasmin elutes. This is explained by the fact that in this large pore gel, the two proteins overlapped with each other (Fig. 2e) , as determined by Western blotting of mouse plasma fractionated on an open column of similar porosity. To further verify the binding of copper to transcuprein and albumin in the mouse, we added tracer 64 Cu(II) prior to fractionation. The elution profile in Fig. 2f is exactly the same as that found previously for the rat (Weiss and Linder 1985; Linder 1991 , Liu et al. 2007 ). Two 64 Cu-binding peaks are evident: transcuprein (identified as alpha-1-inhibitor-3) eluting in the void volume on Sephadex G150; and albumin eluting later on.
Copper profiles of human and rat serum/plasma fractionated on the Biosep 4000 column showed certain differences from the mouse data. Analyses of human plasma obtained from five individuals showed one major and three minor copper peaks (Fig. 3a) . Peak 1 eluted at 14.1 min (Mr about 680 k) and accounted for 5-10% of the total serum Cu. This Mr is close to that of the major human macroglobulin, alpha-2-macroglobulin (Sottrup-Jensen 1989), the human transcuprein (Liu et al. 2007) , which is a tetramer of 180 kDa subunits-in contrast to the monomeric rodent macroglobulin, alpha-1-inhibitor-3, eluting at 15.5 min (Fig. 2a) . Pure alpha-2-macroglobulin, purified from human plasma by size exclusion and Cibacron affinity chromatography (Lonberg-Holm et al. 1987 ) eluted with the same retention time. Peak 2 (Fig. 3a) contained approximately 65% of the total serum Cu and eluted at a time corresponding to ceruloplasmin (16.9 min). Peak 3 contained about 15% of the copper, and eluted at 18.7 min as a shoulder on peak 2, with a retention time comparable to albumin. An additional, minor copper-containing component, eluting at about 22 min (about 15 kDa; also seen in mouse plasma) was observed as well.
Rat plasma had a very similar overall profile to that of the human (Fig. 3b) , except that the copper eluting with macroglobulin/transcuprein (before the ceruloplasmin peak; peak 3) was approximately 450 rather than 680 kDa, consistent with rodent versus human macroglobulins (Sottrup-Jensen 1989) . Collectively, the results confirm that ceruloplasmin is the most dominant copper binding protein in the blood plasma/ serum of several mammals, but that it is only one of several proteins accounting for the total copper in this fluid, with other components carrying a substantial portion of the metal, and particularly so in the mouse.
Copper binding components of organ cytoplasms
To detect and compare (with published data for the rat) the major copper binding components of mouse tissue cytoplasms, samples of 100,000g supernatants from kidney, liver, heart, spleen, lung and brain homogenates of the same mice used for plasma analysis were fractionated on a Biosep 4000 HPLC column and analyzed by ICP-MS. Comparable copper profiles were observed for all of the tissues (Fig. 4) . A significant copper binding component (peak 1) eluted close to the void volume (12 min; [1000 kDa) and, with the exception of the brain, a second peak was observed at approximately 18 min (Mr about 110 k). In all but heart and brain, the dominant copper peak (peak 3) eluted at about 20 min (Mr about 45 k). In the heart (Fig. 4b) , there was a separate peak at about 23 min (Mr about 11 k) (peak 4), which coincided with shoulders in that region of the elution profiles for other tissues (Fig. 4a-c) . The brain, which had the lowest amounts of cytosolic copper, had a broad peak encompassing the region of peaks 3-4 in the other tissues (Fig. 4c) . The major copper peak at 20 min (45 kDa) coincided precisely with the largest peak for Zn in the kidney (Fig. 4d ) and liver (data not shown) and was tentatively identified as Cu/Zn superoxide dismutase (about 35 kDa). Zn also eluted with peak 2 for copper in the kidney, and in the void volume. There was no evidence for a discrete peak for metallothionein at 7 kDa (*24 min), although an 11 kDa peak containing Cu with traces of Zn was observed in heart cytosol ( Fig. 4e) , which is consistent with the known retention characteristics of metallothionein in size exclusion chromatography (Kagi and Nordberg 1979) . Lack of reliable antibodies for mouse Cu/Zn superoxide dismutase and metallothionein prevented confirmation of the identities of these components.
Effects of injections of excess copper, as 65 
Cu
To determine how large doses of copper would be accommodated by and eliminated from these various binding proteins and whole organs, mice were injected with a total of 141 lg 65 Cu(II)-NTA, given in five injections (of 25-30 lg) over 14 h. The total dosages injected were estimated to be 3-4 times the copper already present in a 30 g mouse and were administered to ensure sufficient enrichment of 65 Cu in organs and cytosolic components beyond the liver for analytical precision. The excess copper produced no obvious changes in the behavior or activity of the mice, indicating a good toleration.
Pairs of mice were euthanized at various times after the last 65 Cu injection to analyze the distribution of 65 Cu. Figure 5 shows the calculated values for the distribution of injected (extrinsic) 65 Cu in the various mouse organs, as well as for preexisting, intrinsic 63 Cu and 65 Cu, 2 h ( Fig. 5a ) and 24 h (Fig. 5b ) after the last 65 Cu injection. Values were calculated from the measured 65 Cu and 63 Cu concentrations and the natural 63 Cu/ 65 Cu ratio (see ''Methods''). Analysis of the partitioning of the extrinsic 65 Cu in the various tissues 2 h after the last injection showed that the liver had by far the highest concentration, followed by the kidney, with minimal accumulation in heart and brain. Extrinsic 65 Cu in the plasma was also greatly elevated, being 39 the intrinsic content 2 h post injection, as would be expected, since the copper was distributed to the tissues through the blood. Indeed, analyses of plasma samples 30 min after the last 65 Cu injection showed levels of extrinsic 65 Cu in plasma 59 higher than 90 min later (at 2 h; data not shown). This implied rapid loss of the copper from the circulation. Levels of extrinsic 65 Cu in plasma fell to about twice normal levels by 24 h (Fig. 5b) , while minimal losses were observed from the liver. The total concentrations of copper in heart, spleen and brain increased significantly between 2 and 24 h post injection. These increases were caused by an influx of intrinsic copper, suggesting that the injected 65 Cu had induced displacement and transfer of preexisting metal from other sites in the animal. Figure 6 shows the temporal changes in extrinsic 65 Cu in the tissues and plasma from 30 min after the last injection until 24 h (a) or 2 weeks (b) later, expressed as a percentage of the administered dose. (Values for plasma and brain in the figure have been multiplied for visual clarity.) Again, the Fig. 4 Size exclusion HPLC separation of copper (and zinc) binding components in cytoplasm of tissues of normal adult female mice. Samples of cytoplasm obtained by centrifuging fresh homogenates for 1 h at 105,000g (see ''Methods'') were applied to the same large-pore size exclusion HPLC column as for plasma (Figs. 2, 3 ) and plotted in the same way.
Representative 63
Cu elution profiles for (a) liver and kidney, (b) heart and spleen, (c) lung and brain have been superimposed. The Mr values for peaks/shoulders 1-4 were calculated to be [1000, 110, 45, and 11 k, respectively. In d and e, the zinc elution profiles for the same samples of kidney (d) and heart (e) cytosol have been superimposed on those for copper Biometals (2008) 21:525-543 533 overwhelming importance of liver deposition of the injected copper is apparent, the kidney being of secondary importance, and relatively little deposition occurring in any of the other organs analyzed. Data from liver taken 30 min after the last (of 5) injection of 65 Cu showed that this organ contained approximately 30% of the total administered dose. By 6-24 h post-injection, over 50% of the dose was retained in the liver, after which time rapid loss was observed. Thus, from day 1 to day 7, the liver eliminated 40% of the injected copper, a further 17% being lost by the end of the second week. This indicates a highly efficient excretory mechanism, presumably involving the bile (Burstein et al. 2005; Harada et al. 2005; Linder 1991 Linder , 2002 Linder and Roboz 1986; Turnlund et al. 1989 Turnlund et al. , 1998 . Indeed, mass balance calculations of the total extrinsic 65 Cu content of the analyzed tissues at each time period showed incomplete recovery of the administered dose, with no more than 60% being accounted for at any time tested. This is consistent with either a very high initial rate of excretion (during the period of isotope administration prior to the last injection) and/or partitioning into tissues such as the bone, skin, viscera, etc. that were not analyzed. The changes in the proportion of the total extrinsic 65 Cu accounted for by the cytoplasm of each organ, and temporal changes in these proportions, were also calculated (Table 1 ). In the case of the liver, most of the extrinsic 65 Cu was cytoplasmic after 24 h, and this proportion remained essentially constant for the duration of the experiment (data not shown). In the case of the kidney, just over half was initially in the cytoplasm, and this declined slowly over the following 7-14 days. In this respect, it is of interest to note that the kidney remained enriched with 65 Cu longer than the liver (Fig. 6b) , and that most of the extrinsic 65 Cu remaining at 7 and 14 days was not in the cytoplasm (Table 1) . Similarly, the spleen showed a marked reduction in the proportion of extrinsic 65 Cu retained in the cytoplasm. In contrast, the cytoplasmic content of extrinsic 65 Cu in the brain and lung increased from initial values of about 65% to account for more than 89% of the retained dose by 7-14 days. However in heart cytoplasm, the proportion stayed relatively low and constant.
To detect and compare the changes in enrichment of 65 Cu in the cytoplasmic copper binding proteins, samples from the liver (Fig. 7a), kidney (Fig. 7b ) and brain ( Fig. 7c ) 2 h, 6 h and 14 days after the last 65 Cu injection were fractionated on the Biosep 4000 column. The relative degree of Cu enrichment of each protein was determined by comparing the increases in the absolute intensities of the 65 Cu signal and the 63 Cu/ 65 Cu ratios at the peak centroid. In the untreated mice, the isotopic ratios of Cu 63 Cu/ 65 Cu were invariably lower than the expected natural geological abundance, presumably due to interferences caused by the buffer, averaging 1.70 ± 0.13 (Mean ± SD; N = 9). Nevertheless, following injection of 65 Cu, a pronounced decrease in the 63 Cu/ 65 Cu ratios was noted in all the liver and kidney components (Fig. 7a,  b) . In contrast, the 63 Cu/ 65 Cu ratios in the brain showed little change over the treatment period (Fig. 7c) indicating minimal accumulation of 65 Cu in the protein components of this organ.
In general, the elution profiles and patterns of turnover of 65 Cu in the fractionated cytoplasmic proteins of liver and kidney (Fig. 7a, b) were very similar. In addition to having elevated 65 Cu in the void volume and 110 kDa components (peaks 1 and 2), and in the dominant 45 kDa peak (No. 3) seen in untreated mouse cytoplasm (Fig. 4a) , most of the administered extrinsic 65 Cu 2 h post injection was bound by peaks 4 and 5 (Mr about 28 and 11 k). Neither peak 4 or 5 bound significant amounts of Cu in control animals (Fig. 4a, 7a, b, dashed line) . After the 65 Cu treatment, the general background signal (between 12 and 17 min) of 65 Cu in the chromatogram, increased markedly as well. In the liver (Fig. 7a) , there was considerably less copper at 6 h than 2 h, with 65 Cu being eliminated most rapidly from the largest and the 28 kDa component and least rapidly from the 11 kDa moiety. Similar patterns of 65 Cu depletion were observed in the cytoplasmic components of the kidney (Fig. 7b) , although significantly less 65 Cu was associated and consequently lost from the void volume peak. Turnover of the metal in peak 3 was significantly more rapid in the liver than the kidney. There was almost complete turnover of metal (or specific loss of the injected 65 Cu) in the former (but not the latter) by day 14. By 14 days post injection, much of the injected copper had been eliminated from the liver and kidney cytosol, although the isotopic ratios clearly indicated long-term retention of a proportion of the administered 65 Cu. At this time, the profiles of 63 Cu and 65 Cu on the various peaks were closely aligned, implying exchange and equilibration of the intrinsic and extrinsic Cu between the cytoplasmic proteins in these organs (Fig. 7a, b) . Unlike the liver and kidney, the ratios of 63 Cu/ 65 Cu in the cytosolic components in Kidney (up to 6 h) 0.19 ± 0.06 (6) 0.11 ± 0.04 (6) 55
(7-14 days) 0.039 ± 0.023 (4) 0.015 ± 0.009 (4) 38 Heart (up to 7 days) 0.092 ± 0.026 (10) 0.023 ± 0.007 (10) 25
Lung (up to 7 days) 0.084 ± 0.013 (8) 0.058 ± 0.009 (9) Brain (up to 24 h) 0.0085 ± 0.0027 (8) 0.0056 ± 0.0019 (7) 65 (7-14 days) 0.0072 ± 0.0019 (4) 0.0069 ± 0.0023 (4) 96 Biometals (2008) 21:525-543 535 the brain did not change significantly from that of the untreated mice, even 30 min (data not shown) and 2 h post injection. The pool of copper in this organ was thus essentially pharmacokinetically isolated from the administered injection of 63 Cu. The response of the blood plasma proteins to the excess copper was also examined. Figure 8a -e show that 30 min to 6 h post injection, most of the extrinsic 65 Cu was associated with albumin (peak 3, at 18.7 min). In comparison, ceruloplasmin and macroglobulin (peaks 1 and 2, at 15.5 and 16.8 min) bound much less 65 Cu, although their isotopic ratios still indicated a substantial enrichment with 65 Cu. Plasma concentrations of 65 Cu diminished rapidly, as shown by the increase in the 63 Cu/ 65 Cu peak ratios from 30 min to 2 h after the last isotope injection (Fig. 8a,  b) , and subsequently between 6 h and 14 days after injection (Fig. 8c, d ). It should be noted that except right after injection, when albumin was primarily responsible for binding the excess copper, enrichment of the three main copper components (macroglobulin, ceruloplasmin and albumin) appeared to be about the same, consistent with the rapid entry, turnover and equilibration of the copper in these components.
Discussion
Our analyses of copper in the plasma/serum and tissues indicates that its distribution in the mouse is similar to the human and rat but also differs significantly in some aspects. The most striking difference is that mice have less than half as much copper in the circulating blood plasma as humans and rats. This is consistent with our earlier findings (Montaser et al. 1992) and is also in accord with the observation that mice also have less copper in their livers and kidneys. Thus, Meyer et al. (2001) reported liver concentrations of 2.6 ± 0.2 lg/g for 10-12 week old mice of the same strain used here, which is significantly lower than the values of 4.6 ± 1.1 and 6.2 ± 0.8 reported for rats and humans, respectively (Means ± SD, N = 9-23; Linder 1991. Similarly, mouse kidney values of [The numbering of peaks is not identical to that in the untreated mice (Fig. 2) , where an additional component (peak 1) was detectable. Here, peak 2 (rather than 3) is ceruloplasmin] 3.8 ± 0.1 (Meyer et al. 2001) are significantly less than the values of 7.9 and 12 for rats and humans, respectively (Linder 1991) . Heart and brain did not show marked interspecies differences.
As concerns the copper binding components of plasma and serum, we report here for the first time the distribution of copper in the circulation of the mouse together with a refined picture for the human and rat. The current analyses confirm our previous studies and those of others that ceruloplasmin contains approximately two-thirds of the total copper in human and rat blood plasma (Barrow and Tanner 1988; Gless et al. 1992; Weiss and Linder 1985; Wirth and Linder 1985) . This is contrary to the 95% still often quoted from the old and outdated literature (see Weiss and Linder 1985) . Approximately 15% of the plasma copper from humans and rats eluted in the position of albumin, which is known to bind one copper ion very tightly at the N-terminus (Linder 1991; Masuoka et al. 1993) ; and 5-10% eluted with components of Mr consistent with the transcupreins alpha-2-macroglobulin (in humans) or alpha-1-inhibitor-3 (in rats) which bind copper even more tightly than albumin (Linder 1991 (Linder , 2002 Liu et al. 2007; Masuoka et al. 1993) . Our values for unclotted human blood plasma differ from those of Gless et al. (1992) for serum who reported 2.3%, 84% and 14% of total copper coeluting with alpha-2-macroglobulin, ceruloplasmin and albumin, respectively. This difference may relate to the observation that a substantial proportion of the large (750 kDa) alpha-2-macroglobulin can become trapped in the clots removed when serum is harvested from whole blood (Salvatore Pizzo personal communication). The current studies indicate the mouse has a significantly smaller proportion of its plasma copper (about half) associated with the ceruloplasmin peak than humans and rats, and more associated with the macroglobulin/transcuprein and albumin peaks (about 10% and 25%, respectively).
Using size-exclusion HPLC-ICP-MS, we detected additional copper binding components in plasma, not previously reported. The first (Mr 15 k) was present in humans and mice and might be metallothionein, which is known to occur in serum (Garvey and Chang 1981; Mehra and Bremner 1983) and to elute as a seemingly larger protein (Kagi and Nordberg 1979) . (Reliable antibodies were not available to verify the identity of this component.) A second in mice and humans was larger than transcuprein, eluting close to the void volume. A third (*45 kDa) was evident in plasma from all three species. It is noteworthy that no very low molecular weight copper components were detected. Thus, ceruloplasmin is clearly only one of a number of proteins in the blood fluid that bind quantitatively significant amounts of copper.
Although albumin normally accounts for only 15-25% of the copper in human, rat and mouse blood plasma, it has the potential for binding a great deal more. Indeed, calculations indicate that the albumin in 1 ml of plasma can theoretically bind more than 600 lg of copper with high affinity. This is many orders of magnitude more than that normally bound [about 100 ng/ml in mouse and 120-200 ng/ml in human plasma (Barrow and Tanner 1988; Linder 1991) ]. This available binding capacity is clearly illustrated in the current study where approximately 28 lg 65 Cu was sequestered by the circulating albumin of one ml of mouse plasma within 30 min of the last injection (one ml being about equivalent to the total plasma volume of the mouse). Thus, albumin may be viewed as an important component of the buffering system of most mammals that acts in concert with other transfer and transport proteins to protect against acute copper toxicity that could otherwise be induced by free copper ions (Linder 2002; Rae et al. 1999) .
The cytoplasmic distribution of copper in all of the major organs examined in the mouse showed its consistent association with 2 or 3 major components that were separable by size exclusion HPLC. This finding is comparable to earlier reports for Cu distribution in a more limited number of rat organs. Thus, rat liver, kidney (and intestinal) cytosols fractionated on Sephadex G75 or 100 showed three consistent components, one eluting in the void volume, one at about 35 kDa and another at about 15 kDa (Linder 1991; Norton and Heaton 1980; Sharma and McQueen 1981; Terao and Owen 1973) . It has generally been accepted that the second and third peaks contain Cu/Zn superoxide dismutase and metallothionein (MT), respectively (Linder 1991) . However, these reports preceded awareness of several other proteins, including the copper ''chaperones'', ATOX1 and COX17, presumed to be present in most cells, and which transport copper to the TransGolgi network and mitochondria, respectively. Since these are very similar to MT in apparent size (Linder 2002 ), they will contribute to copper in the 15 kDa peak range. These proteins and MT did not separate very well from Cu/Zn SOD on the larger pore columns used in this study, generally eluting together in a broad (and large) peak. SOD and the others were best differentiated by comparing the heart (which has mainly the reputed MT/ATOX1/COX17 peak) with the kidney (which has mainly the SOD peak). The leading edge of the latter also co-eluted with a major Zn peak, consistent with Cu/Zn SOD. However, the SOD chaperone, CCS, is about the same size as SOD (Huffman and O'Halloran 2001) and would also elute there. A monomeric (48 kDa) form of S-adenosyl homocysteine hydrolase (Bethin et al. 1995) , which also binds copper tightly and accounts for a significant portion of liver copper in the cytoplasm, should elute just ahead of SOD and would contribute to this peak as well. A dimer of the hydrolase might also account for the 110 kDa component in the various cytosols, since it binds copper as well, at least in liver, kidney and brain (to decreasing degree). Aggregates of the 23 kDa COMMD proteins [which include MURR1/COMMD1 implicated in biliary excretion and defective in the Bedlington terrier; Burstein et al. 2005) ] also probably contribute to the copper components eluting in the 20-50 kDa range, as should the dimeric ''S100b'' protein (Nishikawa et al. 1997 ) particularly prevalent in brain. Thus, the large and broad copper peak in the 20-50 kDa region is presumably comprised not just of SOD and MT but several other proteins. Clearly, further studies involving more refined and powerful separatory techniques, such as multidimensional HPLC together with confirmatory molecular identification by techniques such as MALDI-TOF are necessary to resolve the specific molecules involved.
The identity of the largest copper binding component is still a complete mystery. Although a number of new, larger copper binding proteins have recently been identified in mammalian cells, these are bound to intracellular membranes or the plasma membrane (ATP7A and B; hephaestin; DMT1; CTR1; CTR2) (Arredondo and Nunez 2005; Linder 2002; Puig and Thiele 2002; van den Berghe et al. 2007 ). Prior studies had indicated it was larger than 100 kDa. Our current work using a larger pore column shows it to be a great deal larger ([1000 kDa). The absence of very small copper components may again be noted. Although evidence from cell culture has shown that copper can bind the tripeptide, glutathione, when given in high doses and preserved under anaerobic conditions, it is questionable whether this happens in vivo, since others have shown that cytoplasmic proteins can successfully out-compete GSH for Cu (Ohta et al. 2001) .
Our observations that mice were able to tolerate the potentially toxic effects of large doses of copper and were able to rapidly eliminate the metal is consistent with previous observations made in humans and rats (Linder and Roboz 1986; Turnlund et al. 1989) . The level of tolerance exhibited by the mice in the current study was particularly impressive. Based on the copper concentrations of various organs and tissues in mice and rats, we estimate that an adult mouse of 25-35 g contains a total of 35-50 lg copper. In this study we injected of 25-30 lg copper 59 over 14 h, for a total of about 141 lg, a dosage three times greater than the amounts of copper already present. This was not only tolerated (the mice did not alter their behavior after an injection) but our analyses of the amounts of copper remaining in the animals at various times after the last injection indicated that elimination was very rapid. Consistent with the well-established observation that the liver and kidney take up most of the new copper entering the circulation (Linder 1991) , these organs were the only ones examined that responded to the copper treatment with large increases in tissue copper accumulation. Thirty minutes after the last injection, liver concentrations of copper (most of which was extrinsic 65 Cu) were 8x higher than normal, while those in the kidney were 29 the normal. The liver accounted for 30-55% of the total 65 Cu administered in the first hours after the last injection, the kidney only about 5%. Mass balance calculations indicated only 65% of the injected dose could be accounted for in the organs examined. This implied that either a considerable portion of the dose may have been already excreted during the 14 h injection period, or that the 65 Cu was sequestered in tissues not analyzed, such as the skin, viscera and skeleton. In humans, the bones are known to account for 40% of the total body copper (Linder 1991) , and the release of newly absorbed 65 Cu from these compartments back into the blood would explain the continuing buildup of 65 Cu noted in the liver up to 6 h after the last injection. This buildup could not be reconciled with the fall in blood plasma 65 Cu alone, which could account for only 10-20% of that copper.
Over the following 2 weeks, the liver copper content showed an exponential decline, with a halflife of about 4 days. Except for the kidney, which remained enriched longer due to 65 Cu retained in non-cytoplasmic components (Table 1) , similar rates of decline were observed in other organs, with only about 20% of the injected 65 Cu dose remaining after 7 days and approximately 5% after 14 days. This is similar to our previous findings for whole body copper in rats where we followed the loss of ng quantities of injected 67 Cu for 2 weeks (Linder and Roboz 1986) . Most of the radioisotope turned over with a half-life of 2.5-3 days; a second compartment had a much longer half-life (8-10 days). Prior injection of 25 lg of copper (about 10% of the estimated total in a 150 g rat) increased liver copper concentrations about 50% but did not alter the turnover rate. The same and a previous study (Owen et al. 1975) indicated that 10-14% of the injected copper was lost in the bile and feces (and about 2% in the urine) over the first 24 h. All of this is consistent with the established concepts that (a) copper homeostasis is mainly controlled at the level of excretion, and mainly by the liver, which eliminates most of the excess through the bile (Linder 1991) ; (b) with the exception of dogs and sheep and individuals with specific genetic defects, such as in ATP7B in Wilson disease, most mammals are capable of dealing with unexpectedly large intakes of copper.
Finally, the current studies have shown the utility of stable isotopic Cu to study the long-term metabolism of the metal over physiologically relevant time scales beyond those feasible with radioisotopic forms of the element. Relatively small doses of the stable copper isotope, 65 Cu, have been used successfully in humans to study whole body intestinal absorption, transport and excretion kinetics, with the finding that long term retention and excretion of copper are inversely related to copper status and intake, those with low intakes retaining more and excreting less and vice versa (Turnlund et al. 1989 (Turnlund et al. , 1998 . Studies in humans are obviously more limiting, however, and do not allow us to follow the turnover of copper in specific organs and their proteins, which is the advantage of using experimental animals. The current feasibility studies have shown that stable isotopic copper 65 Cu administered i.p. to mice results in the detectable enrichment of specific copper proteins in all organs but the brain, and particularly so in the liver and kidney. Although large doses of 65 Cu were administered, the data indicate that physiologically relevant doses of stable isotopic copper could be used in conjunction with HPLC-quadrupole ICP-MS (or more preferably, multicollector magnetic sector instruments) to successfully model the long-term homeostatic capabilities and turnover of copper in the individual binding components. This would be particularly possible in the tissues most actively involved in the metabolism and processing of this essential but potentially toxic trace element.
